Fig. 1: Experimental design. | npj Vaccines

Fig. 1: Experimental design.

From: Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease

Fig. 1

a Schematic of vaccine constructs with all RABV and foreign proteins indicated. Red diamond indicates the attenuating mutation at amino acid 333 of RABV-G. N nucleoprotein, P phosphoprotein, M matrix protein, G glycoprotein, L RNA-dependent RNA polymerase, LASV-GPC Lassa virus glycoprotein precursor, SARS-CoV-2 S1 severe acute respiratory syndrome coronavirus 2 spike protein subunit 1, ED31 31 amino acids of the ectodomain, TM transmembrane domain, CD cytoplasmic domain. b Table outlining the vaccine groups and expected experimental outcomes. c Experimental timeline. Red droplets indicate blood draws, rhabdovirus and syringe indicate immunization, and the arenavirus represents the LASV challenge. Figure made with BioRender.com.

Back to article page